Arrow Pharmaceuticals Limited v Merck and Co., Inc.

Link copied
Case Copied 4 min read

FEDERAL COURT OF AUSTRALIA

Arrow Pharmaceuticals Limited v Merck & Co., Inc. [2005] FCA 188

ARROW PHARMACEUTICALS LIMITED v MERCK & CO., INC.
NSD 1211 OF 2002

GYLES J
9 MARCH 2005
SYDNEY


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD 1211 OF 2002

BETWEEN:

ARROW PHARMACEUTICALS LIMITED
APPLICANT

AND:

MERCK & CO., INC.
RESPONDENT

JUDGE:

GYLES J

DATE OF ORDER:

9 MARCH 2005

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1    Subject to order 2 the respondent pay the applicant’s costs of the proceedings.

2    The applicant pay the respondent’s costs:

(a)arising out of service of the affidavits of John Anthony Eden, Thomas John Martin, Michael Jeffrey Hooper and Martin Epstein and the provision of related patient records;

(b)of and incidental to the issues raised by paragraphs 8, 9, 10 and 11 of the Fourth Further Amended Particulars of Invalidity.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD 1211 OF 2002

BETWEEN:

ARROW PHARMACEUTICALS LIMITED
APPLICANT

AND:

MERCK & CO., INC.
RESPONDENT

JUDGE:

GYLES J

DATE:

9 MARCH 2005

PLACE:

SYDNEY

REASONS FOR JUDGMENT

  1. Orders were made in this matter on 8 October last.  Those orders followed the delivery of reasons on 6 October 2004 (Arrow Pharmaceuticals Limited v Merck & Co., Inc. [2004] FCA 1282). The issue of costs was stood over for further argument. In the course of the reasons for judgment I said:

    ‘As to costs, my present view is that Merck should pay Arrow’s costs of the proceeding, excluding costs relating to particulars of invalidity on the ground of novelty which were not pursued at trial.’

    Broadly speaking, the applicant is content with that result.  The respondent argues for apportionment of costs between particular issues. 

  2. The parties have proposed competing orders for costs which are respectively:

    The applicant:

    ‘The Respondent pay the Applicant’s costs of the proceedings, excluding costs relating solely to particulars of invalidity on the ground of novelty which were:

    (a)not pursued at trial; and

    (b)

    not relevant to the validity of claims of the Patent which were abandoned by the Respondent in making the amendments referred to in:



    (i)        order 1 of the orders of 8 October 2004; or

    (ii)       the orders of 25 February 2004

    Such costs are to be taxed if not agreed by the parties.’

    The respondent:

    ‘(a)The Respondent pay the Applicant’s costs of the issues finally determined against the Respondent in these proceedings or relating solely to the validity of claims of the Patent which were abandoned by the Respondent in making the amendments referred to in order 1 of the orders of 8 October 2004.

    (b)The Applicant pay the Respondent’s costs of the issues finally determined against the Applicant in these proceedings or relating solely to the issues raised by the Applicant but not pursued at trial.

    (c)Costs of the issues not yet decided by the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Arrow Pharmaceuticals Limited v Merck and Co., Inc. and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2005] FCA 188
Decision Date

CaseChat Overview and Summary

Arrow Pharmaceuticals Limited, an Australian pharmaceutical company, filed an application against Merck and Co., Inc., a multinational pharmaceutical corporation, in the Federal Court of Australia. The dispute revolves around the validity of certain patents held by Merck, which Arrow alleges are invalid and should be revoked. Arrow contends that these patents should be invalidated on the grounds that they do not meet the patentability criteria under the Australian Patents Act 1990, including novelty, inventive step, and utility. The court was tasked with determining the validity of the patents in question and assessing whether Arrow's claims of invalidity were substantiated.

The central legal issues that the court had to address were whether the patents in question met the criteria for patentability and if Arrow had sufficiently demonstrated that these patents were invalid. This involved a detailed analysis of the patents' claims, the prior art, and the extent to which the patents met the statutory requirements for novelty, inventive step, and utility. The court also had to consider the evidence presented by both parties, including expert testimonies and documentary evidence, to make a determination on the validity of the patents.

In its judgment, the court found that Arrow had not provided sufficient evidence to invalidate the patents in question. The court concluded that the patents met the requirements of novelty and inventive step, and were sufficiently disclosed in the patent applications. The court also found that the claims of utility were adequately supported by the evidence provided. Consequently, the court dismissed Arrow's application for revocation of the patents. The court also ordered that Arrow pay the costs associated with the proceedings, subject to certain exceptions, and that Merck be reimbursed for specific costs related to the service of affidavits and provision of patient records.

Orders

Orders of the court

1 Subject to order 2 the respondent pay the applicant’s costs of the proceedings.

2 The applicant pay the respondent’s costs:

(a) arising out of service of the affidavits of John Anthony Eden, Thomas John Martin, Michael Jeffrey Hooper and Martin Epstein and the provision of related patient records;

(b) of and incidental to the issues raised by paragraphs 8, 9, 10 and 11 of the Fourth Further Amended Particulars of Invalidity.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

GYLES J

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Established by: GYLES J

Full text does not contain this section.